A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

开始日期2023-10-16

申办/合作机构

Celgene Corp.

[+1]

NCT06154902 / Active, not recruitingN/A

ABE-DESCART Study: Characterization and Outcomes of Patients With Relapsed and Refractory Multiple Myeloma Eligible for Treatment or Treated With Abecma© (Idecabtagene Vicleucel) in Real World Setting in France. A Database Analysis Based on the DESCAR-T Registry

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

开始日期2022-07-29

申办/合作机构

Bristol Myers Squibb Co.

NCT05032820 / Active, not recruiting临床2期IIT

Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMTCTN1902

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).

开始日期2022-01-05

申办/合作机构

National Marrow Donor Program

[+4]

100 项与艾基维仑赛相关的临床结果

登录后查看更多信息

100 项与艾基维仑赛相关的转化医学

登录后查看更多信息

100 项与艾基维仑赛相关的专利（医药）

登录后查看更多信息

118

项与艾基维仑赛相关的文献（医药）

2024-02-01·Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy

Letter

作者: Le Guillou Guillemette, Hélène ; Pronier, Charlotte ; Thibault, Vincent ; Roussel, Mikael ; Maillard, Anne ; Stefic, Karl

2024-01-09·Blood advances

Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Article

作者: Sborov, Douglas W ; Blue, Brandon J ; Badros, Ashraf Z ; Lin, Yi ; Ferreri, Christopher ; Nadeem, Omar ; Oswald, Laura B ; Dillard, Christen M ; Afrough, Aimaz ; De Avila, Gabriel ; Freeman, Ciara L ; Locke, Frederick L ; McGuirk, Joseph ; Hansen, Doris K ; Dima, Danai ; Shune, Leyla ; Khouri, Jack ; Alsina, Melissa ; Kalariya, Nilesh ; Castaneda Puglianini, Omar ; Hashmi, Hamza ; Davis, James A ; Patel, Krina ; Liu, Lawrence ; Wagner, Charlotte ; Kocoglu, Mehmet H ; Peres, Lauren C ; Nishihori, Taiga ; Sidana, Surbhi ; Anderson, Larry D ; Kaur, Gurbakhash ; Voorhees, Peter ; Atrash, Shebli ; Simmons, Gary

Abstract:

Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 patients with RRMM (28% patients of racial and ethnic minority groups) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence of toxicities and adverse events, response to ide-cel, and survival. This study included 22 (11%) Hispanic, 36 (17%) non-Hispanic Black, and 149 (72%) non-Hispanic White patients with RRMM. Compared with Hispanic and non-Hispanic White patients, non-Hispanic Black patients had higher median levels of C-reactive protein (1.0, 0.8, and 3.5 mg/dL, respectively; P = .02) and baseline ferritin (362.0 vs 307.0 vs 680.5, respectively; P = .08) and were more likely to develop cytokine release syndrome (77%, 85%, and 97%, respectively; P = .04). Although best overall response rate was lower among Hispanic patients (59%) than among non-Hispanic Black (86%) and White patients (86%; P = .01), there were no racial and ethnic differences in progression-free or overall survival. We provide, to our knowledge, the first and largest investigation of clinical outcomes of SOC ide-cel by race and ethnicity. Despite differences in safety and response to ide-cel, our findings encourage the use of ide-cel in all patients with RRMM. These findings should be confirmed in larger samples of diverse patients with RRMM, with longer follow-up time.

2024-01-01·European journal of haematology

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Review

作者: Vucinic, Vladan ; Grieb, Nora ; Platzbecker, Uwe ; Fischer, Luise ; Merz, Maximilian

Abstract:

The introduction of chimeric antigen receptor (CAR) T cells revolutionized treatment of relapsed and refractory multiple myeloma (RRMM) in recent years. Currently, two CAR T cell products—idecabtagene vicleucel and ciltacabtagene autoleucel—are approved in the United States and the European Union to treat patients with three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti‐CD38 antibody. Moreover, seminal phase III trials of both agents in earlier lines of therapy have been published recently. Despite unprecedented rates of deep and lasting remissions in RRMM, there are still areas of uncertainty regarding the optimal use and distribution of CAR T cells in multiple myeloma. In the current review, we discuss the available data on approved CAR T cell products as well as unmet clinical needs and ongoing developments to optimize usage of this promising treatment modality in multiple myeloma.

605

项与艾基维仑赛相关的新闻（医药）

2024-06-27

·药渡

【药企裁员风波渐退】六月汇总

来源：药渡撰文：五月编辑：哦呼六月药企裁员潮渐退，相较于之前数月的密集发布，本月约有7家药企公布了减员计划，如下表所示。 6月药企裁员名单 6月24日近期，G1 Therapeutics公布了其用于评估化疗前给药的曲拉西利（吉西他滨和卡铂；GCb）在转移性TNBC患者中疗效的3期PRESERVE 2试验结果，研究结果显示在风险比（HR）为0.91（p=0.884）的ITT人群（n=187）中未显示出具有统计学意义的治疗效果（图1）。曲拉西利加GCb组的中位总生存期（OS）为17.4个月，而对照组为17.8个月。在两个PD-L1亚组（阳性和阴性）中，中位OS在数值上都有利于曲拉西利组，尽管两者都没有达到统计学意义。不同地区和接受不同类型后续治疗的患者观察到不同的效果;这些发现将进一步评估。在试验中观察到的含GCb的曲拉西利的安全性与先前的研究一致，并且没有发现新的安全信号。与其他曲拉西利研究一致，观察到骨髓保护的证据，包括严重中性粒细胞减少的发生率降低，在接受曲拉西利治疗的患者中，有8%的患者发生严重中性粒细胞减少症，而对照组为29%[1]。图1. G1 Therapeutics公布3 期 PRESERVE 2 试验结果与此同时，G1还宣布将“停止预期雇用员工”。为了坚持到2025年下半年实现盈利的雄心壮志，这家生物技术公司还将“在现有商业组织之外有针对性地裁员，以精简公司”。该新闻稿没有提供关于有多少员工可能受到影响的线索。 6月24日肿瘤生物技术公司eFFECTOR Therapeutics宣布已经开始裁员，包括eFFECTOR首席执行官Stephen Worland博士、首席财务官Michael Byrnes、首席医疗官Douglas Warner医学博士，他们都在上周末停止了他们的职位[2]。根据美国证券交易委员会的文件，该公司预计到6月30日将花费约60万美元用于与裁员相关的一次性费用和现金支出。与此同时，董事会已任命Craig Jalbert担任eFFECTOR的首席执行官、总裁、财务主管、秘书和唯一董事会成员。Jalbert是会计师事务所 Verdolino & Lowey， P.C. 的负责人，拥有三十多年帮助公司倒闭的经验。接下来的部分步骤包括为eFFECTOR的开发计划寻找战略替代方案。这家生物技术公司的主要资产是zotatifin，这是一种选择性的eIF4A抑制剂，正在几项针对实体瘤的中期试验中进行测试。今年4月，eFFECTOR的另一家全资资产tomivosertib在一项针对非小细胞肺癌（NSCLC）患者的2b期试验中未能改善无进展生存期。根据初步分析中提供的所有数据，该公司表示，在一线NSCLC中继续开发该资产没有明显的前进道路。 eFFECTOR还与大型制药公司辉瑞合作开发了一种名为eIF4Ei的临床前资产，该资产也旨在治疗实体瘤。2019年，辉瑞公司在一项独家许可协议中预先支付了1500万美元，与eFFECTOR合作开发真核起始因子4E（eIF4E）的小分子抑制剂，这笔价值5.07亿美元的交易被搁置。 6月21日上个月宣布削减高达25%的劳动力成本Ginkgo Bioworks这个月继续裁员，宣布将裁员158人[3]。 Ginkgo的一位发言人告诉该媒体，这家总部位于波士顿的公司将在下周披露更多的裁员，但没有透露裁员人数。 Ginkgo于2014年成功从硅谷Y Combinator孵化，并拿到风险投资。2021年，Ginkgo通过SPAC（特殊目的收购公司）成功上市，是一家致力于成为开发细胞编程技术的生物合成领域的横向“平台型”企业。 6月20日 Cara Therapeutics在6月14日提交给美国证券交易委员会的文件中披露，该公司将在本月底前裁员70%。就在两天前，Cara Therapeutics宣布了KOURAGE-1研究的剂量探索A部分的结果，该研究评估了口服地非利福林治疗成年感觉异常（NP）患者中度至重度瘙痒的疗效和安全性。与安慰剂相比，口服地非利福林在任何剂量下均未显示出有意义的临床益处，导致公司决定终止其临床项目（图2）[4]。图2. Cara Therapeutics公布KOURAGE-1研究结果截至2024年3月31日，公司拥有约7000万美元的现金、现金等价物和有价证券。在最新的裁员之前，Cara在1月份宣布裁员高达50%。根据其LinkedIn个人资料，总部位于康涅狄格州斯坦福德的公司拥有51-200名员工。 6月13日总部位于英国牛津的Barinthus Biotherapeutics在周三的一份新闻稿中表示，遵循“管道优先权”原则，Barinthus Biotherapeutics将裁员约25%，并估计将现金跑道延长至2026年第二季度。 Barinthus正在将其资源投入到慢性乙型肝炎和乳糜泻的项目上，降低前列腺癌候选者的优先级（图3）。 Barinthus最近在欧洲肝脏研究协会（EASL）大会上公布了其乙型肝炎候选药物VTP-300正在进行的两项II期试验的积极中期数据：VTP-300具有显着降低和维持乙型肝炎表面抗原（HBsAg）水平的潜力，并在慢性乙型肝炎（CHB）患者中达到无法检测到的HBsAg水平。 Barinthus还指出，其主要候选药物VTP-1000的乳糜泻药物的临床前发现“令人鼓舞”，这是将该资产与VTP-300一起优先考虑的原因。图3. Barinthus Biotherapeutics的研发管线据LinkedIn称，Barinthus正在开发新型T细胞免疫治疗候选药物，拥有51至200名员工。 VTP-1000旨在通过诱导麸质特异性T调节细胞和减少麸质特异性T效应细胞反应来平衡免疫反应。在疾病模型的临床前研究证明“作用方式和疾病改善”之后，Barinthus表示，它正准备在第三季度将VTP-1000带入临床。 6月12日根据WARN通知，安捷伦科技公司将于8月9日起裁员近200名加州员工，裁员包括CDMO圣克拉拉总部的156名员工，圣巴巴拉县的7名员工，圣地亚哥县的17名员工和佛森的4名员工。公司发言人Sarah Litton告诉SFGATE，裁员是“跨业务和地区”裁员3%的一部分，安捷伦的目标是“适应市场复苏的步伐”。安捷伦报告称，今年第一季度的收入与去年同期相比下降了5.6%。在此之前，该公司在2023年底报告了加州裁员，并于2024年1月生效。 6月6日根据Fierce Pharma报道的一个警告通知，BMS将在2024年剩余的几个月里在新泽西州劳伦斯维尔裁员863人。这家制药巨头在4月份宣布，它将实施一项全面的“战略生产力计划”，以期到2025年节省约15亿美元的成本，包括到今年年底减少约2200个工作岗位。新泽西州裁员的新披露是在3月份 WARN 通知劳伦斯维尔裁员75人之后发布的。据BMS 2024Q1财报，其Q1营收增长了5%，至119亿美元，超过此前115亿美元的预期，但是其Opdivo（纳武利尤单抗）的销售额下降6%，为21亿美元。低于2023年同期22亿美元的收入。此外，CAR-T疗法Abecma受”持续竞争”和“不利的定价压力”影响，销售额也下降了44%，仅为8200万美元，而去年为1.47亿美元（图4）[5]。图4. 2024Q1 BMS主要肿瘤产品销售额参考文献 1. G1 THERAPEUTICS PROVIDES UPDATE ON PHASE 3 PRESERVE 2 TRIAL IN PATIENTS RECEIVING TRILACICLIB PRIOR TO FIRST LINE CHEMOTHERAPY IN METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) 2. The end of eFFECTOR Therapeutics: Oncology biotech winds down after mid-stage fail 3. Biopharma Layoff Tracker 2024:Ginkgo, Cara, Barinthus and MoreCut Staff 4. Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica 5. Bristol Myers Squibb Q1 2024 Results April 25, 2024 编者按：在医药竞争的浪潮中，现金流稳定是药企稳健前行的关键。通过缩减人员、精简产品线等方式来缓解资金压力虽能短期内止血，却难以根治深层次的资金问题。药企需要更全面、更长远的策略来确保资金链的健康与持续。专栏作者五月药物化学硕博，国外博士后，现从事药物研发工作，热爱医药行业，愿与各位同行互相学习、进步，共同见证创新药的发展。 *声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！点击下方“药渡“，关注更多精彩内容股价飙升39%：RNAi疗法时代来临武田制药药物交易风云：近年数据透视其战略布局新动向 100%预防艾滋！吉利德科学创新药物Lenacapavir 3期临床结果喜人点击下方关注，聚焦医药创新一手资讯

高管变更临床3期临床结果

2024-06-27

·PipelineReview

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

– Divestiture Supports Company Focus on Development and Commercialization of Abecma- CAMBRIDGE, MA, USA I June 26, 2024 I 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. The program is based on the original research agreement, established in 2019, which focused on a gene editing therapy for people with Hemophilia A. 2seventy bio will focus exclusively on the commercialization and continued development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb (BMS). “We are pleased to announce the completion of this APA with Novo Nordisk as we believe it will provide the appropriate resources for both the team and the science behind this important program,” said Chip Baird, CEO, 2seventy bio. “Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with Hemophilia A will continue to progress. We are extremely grateful to the 2seventy team members joining Novo Nordisk and thank them for their incredible work. In addition, the divestiture supports 2seventy’s exclusive focus on delivering Abecma to as many patients as possible.” “I am excited that we are expanding our genome editing technology platforms at Novo Nordisk. We are devoted to developing therapies with a curative outlook, including our continued development of a next-generation in vivo genome editing program aiming to offer individuals living with Hemophilia A a lifetime free of factor replacement therapy,” said Karina Thorn, Novo Nordisk, Corporate Vice President, Global Nucleic Acid Therapies Research. “We have been working closely with 2seventy bio colleagues aligned with our collaboration and I am thrilled to welcome them to Novo Nordisk where we together will leverage the megaTAL technology for pioneering therapeutic applications.” Under the terms of the agreement, 2seventy will potentially receive payments of up to $40 million. 2seventy will transfer the Hemophilia A program to Novo Nordisk and the existing collaboration agreement will terminate. Additionally, the divestiture will include transfer of 2seventy bio’s megaTAL technology and a license to underlying intellectual property. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do – TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day. For more information, visit www.2seventybio.com . SOURCE: 2seventy

细胞疗法并购免疫疗法基因疗法引进/卖出

2024-06-27

·Firstwordpharma

Novo Nordisk snaps up 2seventy’s gene editing tech, haemophilia candidate for $40M

2seventy bio sold off another slice of its cell therapy portfolio this week, along with a flagship gene editing tool, as it moves to “focus exclusively” on the commercialisation of the BCMA-targeted CAR-T cell therapy Abecma (idecabtagene vicleucel), which it markets with partner Bristol Myers Squibb. Novo Nordisk will pay up to $40 million to gain 2seventy’s haemophilia A programme, plus rights to its megaTAL gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease. It’s 2seventy’s second pipeline divestment this year as it doubles down on its commitment to Abecma. In January, Regeneron Pharmaceuticals spent just $5 million upfront to gain the biotech’s preclinical and clinical-stage cell therapy pipeline for cancer and autoimmune diseases. For more on the deal, see Spotlight On: Regeneron gains cell therapy knowhow at a bargain.The strategic shift follows a years-long struggle by 2seventy — which was spun out of bluebird bio in 2021 — to make it as an independent unit focused on immuno-oncology cell therapies. The firm had announced plans in September to reduce its headcount by 40%, citing the "macro environment for oncology cell therapy companies and the near-term headwinds."Past partnershipThursday’s deal builds on a 2019 agreement between the Danish drugmaker and bluebird bio to develop in vivo genome editing treatments for haemophilia and other genetic diseases.At the time, the partnership was only expected to last three years, with the goal of developing a haemophilia A treatment that can correct FVIII-clotting factor deficiency.Along with acquiring the haemophilia asset, Novo Nordisk will also gain all 2seventy employees involved in the programme.

细胞疗法并购基因疗法免疫疗法

100 项与艾基维仑赛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11556	-	L01XX	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Celgene Corp.	2021-03-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性多发性骨髓瘤	临床3期	美国	中美上海施贵宝制药有限公司	2022-01-30
复发性多发性骨髓瘤	临床3期	美国	2seventy Bio, Inc.	2022-01-30
BCMA阳性多发性骨髓瘤	临床1期	美国	Celgene Corp.	2015-12-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


not available (ASCO2024)	N/A	多发性骨髓瘤	351	idecabtagene vicleucel	夢繭窪夢蓋顧構構製鬱(築鬱艱憲壓壓獵淵憲願) = 網襯膚憲顧廠膚窪顧選憲艱鹹窪憲廠齋願淵鹹 (壓淵選襯襯積窪網鹽蓋 ) 更多	不佳	2024-05-24
				idecabtagene vicleucel	夢繭窪夢蓋顧構構製鬱(築鬱艱憲壓壓獵淵憲願) = 壓築繭積鹹範積鏇選鹽憲艱鹹窪憲廠齋願淵鹹 (壓淵選襯襯積窪網鹽蓋 ) 更多
ASCO2024	N/A	复发性多发性骨髓瘤	-	ide-cel	鹽觸築醖繭網窪廠膚築(鏇鑰憲觸獵鏇網餘顧淵) = 鹹鬱廠鑰壓範壓獵觸鹽夢鏇憲鑰鏇憲鹽獵憲壓 (廠糧顧選壓範壓糧襯壓 ) 更多	-	2024-05-24
NCT03601078 (KarMMa-2, EHA2024) 人工标引	临床2期	难治性慢性淋巴细胞白血病 \| 复发性慢性淋巴细胞白血病二线	35	Idecabtagene vicleucel	衊淵窪鹽觸鹽製醖鬱鏇(鹽選淵膚廠糧願選遞淵) = 憲齋糧鹹鑰醖簾夢鏇顧範齋憲築觸廠願鹽艱積 (壓廠廠齋製獵簾願襯齋, 52-86) 更多	积极	2024-05-14
NCT03651128 (KarMMa-3, Pubmed)	临床3期	浆细胞骨髓瘤难治	-	ide-cel	網廠糧構襯製鑰範網願(願願齋壓醖遞衊築鏇構) = 襯壓簾鑰醖鑰觸夢構鏇廠顧鬱齋憲製夢憲鏇範 (鬱鏇鑰鹹繭壓廠願襯壓 )	积极	2024-04-23
				Standard of care regimens	網廠糧構襯製鑰範網願(願願齋壓醖遞衊築鏇構) = 壓襯餘膚獵遞築築膚獵廠顧鬱齋憲製夢憲鏇範 (鬱鏇鑰鹹繭壓廠願襯壓 )
ASH2023	N/A	复发性多发性骨髓瘤	56	Idecabtagene Vicleucel	壓範廠窪壓觸淵蓋積顧(壓憲獵範製鏇簾繭鬱獵) = 鬱獵淵餘積鑰網製衊壓獵齋窪簾鹹醖餘願簾鹽 (築顧壓廠鏇鬱艱蓋鏇製 ) 更多	-	2023-12-11
				Ciltacabtagene Autoleucel	壓範廠窪壓觸淵蓋積顧(壓憲獵範製鏇簾繭鬱獵) = 窪選淵獵窪鏇鹽襯憲範獵齋窪簾鹹醖餘願簾鹽 (築顧壓廠鏇鬱艱蓋鏇製 ) 更多
Karmma Trial (ASH2023)	N/A	复发性多发性骨髓瘤	120	Standard of Care Ide-cel	獵構夢顧艱醖鬱夢艱壓(齋衊齋醖構簾遞遞願觸) = CRS occurred in 81% (grade ≥3, 4%) of SOC pts vs 84% (grade ≥3, 5%) of KarMMa pts 糧製艱範餘鬱蓋衊製範 (餘繭醖衊壓蓋鑰壓積觸 ) 更多	-	2023-12-11
KarMMa-2 and KarMMa-3 (ASH2023)	N/A	多发性骨髓瘤	74	Idecabtagene Vicleucel (High-risk Multiple Myeloma)	襯衊艱餘醖蓋廠顧齋膚(顧鑰齋糧繭廠壓壓齋壓) = 範膚鏇網製範夢鏇壓選簾觸繭壓廠襯餘衊艱齋 (鹹夢獵遞淵鬱獵積獵網 ) 更多	-	2023-12-11
				Idecabtagene Vicleucel (Standard-risk Multiple Myeloma)	襯衊艱餘醖蓋廠顧齋膚(顧鑰齋糧繭廠壓壓齋壓) = 衊獵觸衊膚簾襯膚製齋簾觸繭壓廠襯餘衊艱齋 (鹹夢獵遞淵鬱獵積獵網 ) 更多
KarMMa-3 (ASH2023)	临床3期	复发性多发性骨髓瘤	-	Idecabtagene Vicleucel (ide-cel)	淵衊餘積觸製顧簾範壓(顧憲壓壓壓糧夢觸糧積) = 壓鑰繭膚築壓獵築餘鹽遞夢網觸膚衊餘窪齋願 (廠衊蓋淵繭鹽艱餘糧醖 )	积极	2023-12-11
ASH2023	临床2期	-	109	Patients with TCE RRMM receiving ide-cel	顧繭選膚窪製網艱積鏇(鹽淵壓繭鏇築選膚構衊) = 壓鹹齋簾積觸選選膚淵蓋鬱願築鏇繭夢廠鏇醖 (醖襯艱鬱艱製願糧觸繭 ) 更多	-	2023-12-11
ASH2023	N/A	多发性骨髓瘤	76	Idecabtagene Vicleucel	網獵夢積鏇齋範繭積鬱(願範壓壓遞廠網夢艱網) = 艱鹽鹹壓鹹艱憲淵壓艱膚簾壓顧繭願獵願夢襯 (鏇積構鏇壓網鬱窪繭願 ) 更多	-	2023-12-09
				Ciltacabtagene Autoleucel	網獵夢積鏇齋範繭積鬱(願範壓壓遞廠網夢艱網) = 簾壓築築壓觸願觸遞顧膚簾壓顧繭願獵願夢襯 (鏇積構鏇壓網鬱窪繭願 ) 更多